PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27816545-0	2017	Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.	abemaciclib	23-32	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	89-94	
27816545-6	2017	Mechanistically, LY2835219 is likely a competitive inhibitor of ABCB1 and ABCG2 for its competition with [125I]-iodoarylazidoprazosin for photo affinity labeling of the transporters.	abemaciclib	17-26	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	74-79	
27816545-8	2017	In conclusion, these findings revealed a novel role of LY2835219 in reversing ABCB1 or ABCG2-mediated MDR, which may be benefit to the patients with MDR cancer for combinational therapy.	abemaciclib	55-64	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	87-92	
27816545-4	2017	Here, we found that LY2835219 remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo.	abemaciclib	20-29	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	101-106	
27816545-5	2017	Furthermore, LY2835219 significantly increased the intracellular accumulation of doxorubicin (DOX) and rhodamine 123 (Rho 123) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells.	abemaciclib	13-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	150-155